Effects of adenosine 3′:5′-monophosphate and platelet aggregation on thromboxane biosynthesis in human platelets  by Lindgren, Jan Åke et al.
Volume 98, number 2 FEBS LETTERS February 1979 
EFFECTS OF ADENOSINE 3’:5’-MONOPHOSPHATE AND PLATELET AGGREGATION 
ON THROMBOXANE BIOSYNTHESIS IN HUMAN PLATELETS 
Jan Bke LINDGREN, Hans-Erik CLAESSON, Hans KINDAHL and Sven HAMMARSTRGM 
Department of Chemistry, Karolinska Instituter, S-104 01 Stockholm, Sweden 
Received 17 November 1978 
1. Introduction 
The prostaglandin (PC) endoperoxides, PGGs and 
PGHz [l], and thromboxane (TX)A, [2] cause rapid 
aggregation and induce the release reaction in human 
platelets. Aggregating agents, such as collagen and 
thrombin, stimulate release of arachidonic acid from 
platelet phospholipids. This leads to synthesis of 
endoperoxides, thromboxanes, prostaglandins and 
hydroxy acids [3-51. 
Elevation of adenosine 3’: 5’-monophosphate 
(cyclic AMP) levels in platelets prevents aggregation 
[6-8] and the simultaneous production of TXBz 
[9-121. Two mechanisms for the inhibition of 
thromboxane formation have been proposed: 
(1) Inhibition of prostaglandin endoperoxide 
synthase (EC 1.14.99.1) [9]; 
(2) Inhibition of arachidonic acid release from 
platelet phospholipids [lo- 121. 
In the latter reports no inhibition of prostaglandin 
endoperoxide synthase was observed [lo-121. We 
have therefore reinvestigated the effects of cyclic 
AMP on arachidonic acid release and on the conver- 
sion of arachidonic acid to TXBs. The results suggest 
that elevation of cyclic AMP levels inhibits both of 
these reactions in platelets and that the inhibitory 
effect of cyclic AMP on TXBz formation from 
arachidonic acid is not direct but secondary to 
inhibition of platelet aggregation. 
2. Materials and methods 
Blood, withdrawn from healthy donors who had 
ElsevieriNorth-Holland Biomedical Press 
not taken drugs for at least 10 days, was immediately 
mixed with 0.13 vol. 0.1 M trisodiumcitrate. 
Platelet-rich plasma (PRP) and platelet-poor plasma 
(PPP) were prepared as in [ 131. Collagen was 
obtained from Stago Laboratoire, Asnieres, arachidonic 
acid from Nu Check Prep. Inc., Elysian, MN; 
colchicine and indomethacin from Sigma Chemical 
Co., St Louis, MO. PGIz was supplied by the Upjohn 
Co., Kalamazoo, MI. Thromboxane Bz was determined 
by radioimmunoassay [ 141, and arachidonic acid by 
quantitative mass spectrometry [ 151. Cyclic AMP 
was analysed by the protein-binding assay in [16]. 
Before assay the samples were purified as in [13]. 
Platelet aggregation was monitored by the continuous 
recording of light transmission in a Payton dual 
channel aggregometer (Payton Associates Ltd., 
Ontario). 
3. Results 
3.1. Effects of PGI, on cyclic AMP levels and 
collagen-induced arachidonic acid release in PRP 
PRP (4 ml) was preincubated for 2 min at 37°C 
with indomethacin and CaCl, (final cont. 0.01 mM 
and 2.5 mM, respectively) followed by 15 s with 
PGIs (OS-5 ng/ml). Collagen (10 ng/ml) was added 
and the samples were incubated for another 5 min. 
Two aliquots of 0.5 ml PRP were removed, each 
mixed with 0.5 ml 10% (w/v) trichloroacetic acid 
and rapidly frozen for analyses of cyclic AMP 
content. The remaining 3 ml of the samples were 
mixed with 4 vol. ethanol containing [5,6,8,9,11, 
12,14,15-2H,]arachidonic acid (10 l.(g) and frozen 
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Fig.1. Effects of PGI, on cyclic AMP levels and coilagen- 
induced arachidonic acid release. PRP (4 ml) was preincubated 
for 2 min at 37’C with 10 rM indometha~ and 2.5 mM 
CaCl, and then for 15 s with PGI, (O-5 ng/ml). After 
addition of collagen (10 pg/ml), 2 X 0.5 ml aliquots were 
removed and mixed with 0.5 ml 10% (w/v) trichloroacetic 
acid for cyclic AMP determinations. The remaining 3 ml of 
the samples were mixed with 12 ml ethanol containing 
~5,6,8,9,11,~2,14,1S-2H~]arachidonic aci  (10 #g) for 
analyses of arachidonic acid. 
for analyses of free arachidonic acid. Controls 
without PGIZ were treated in the same way. PGIZ 
elevated the levels of cyclic AMP and caused 
inhibition of arachidonic acid release by >90% 
(fig.1). The arachidonic acid levels have been 
corrected for background levels found in PRP. 
3.2. Effects of PGI, on cyclic AMP levels, arachidonic 
acid-induced a~regat~o~ and TXBz synt~~esis in 
PRP 
PRP (0.5 ml) was preincubated for 1 min at 37°C 
with CaC12 (2.5 mM) and for 15 s with or without 
PGI, (25 ng/ml). Arachidonic acid (25-800 bg/ml) 
was then added. After 5 min incubation and 
subsequent addition of indomethacin (10 FM) the 
samples were rapidly frozen for analyses of TXBz 
(fig.2). At Q 100 pg arachidonic acid/ml (which did 
not cause aggregation), TXBz levels were low and not 
influenced by PG12. At > 200 pg arachidonic acid/ml, 
aggregation was induced (not shown) and formation 
of TXBz stimulated. PGIZ inhibited TXBz synthesis 
by 8 1% and 47% at 200 pg arachidonic acid/ml and 
400 pg arachidonic acid/ml, respectively. At 800 pg 
arachidonic acid/ml, PG12 had no effect on the 
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Fig.2. Arachidonic acid-induced TXB, synthesis in 
absence or presence of PGI,. PRP (0.5 ml) was preincubated 
for 1 min at 37°C with CaCl, (2.5 mM) and for 15 s with or 
without PGI, (25 ng/ml). After 5 min incubation with 
arachidonic acid (25 -800 &ml), indomethacin (10 PM) 
was added and the samples were rapidly frozen for 
determinations of TXB,. Control (o --0); PGI, 
(*----0). 
TXBz levels. PGI? prevented platelet aggregation at 
all concentrations of arachidonic acid. 
In other experiments, PRP (0.5 ml) was incubated 
as above in an aggregometer with varying concen- 
trations of PGIZ (O-1000 ng/ml) and arachidonic acid 
(250 @g/ml or 1000 pg/ml). These samples were used 
for determinations of TXBz levels and platelet 
aggregation. Parallel samples were incubated in the 
same way and stopped with 0.5 ml 10% (w/v) 
trichloroacetic acid for measurements of cyclic AMP. 
Figure 3 shows the effects of PGIz on these 
parameters. At both concentrations of arachidonic 
acid,complete inhibition of the aggregation was observed, 
when >, 5 ng PGI,/ml was added. When 2.50 pig 
arachidonic acid/ml was added the formation of 
TXBz was partially inhibited by PGI, (2 5 ng/ml 
caused -75% inhibition). In contrast, no inhibition of 
TXBz formation was observed at the higher 
arachidonic acid concentration. 
3.3. Effects of c~~chicine on cyclic AMP levels, 
arachidonic acid-induced aggregation and TXBz 
synthesis in PRP 
PRP (0.5 ml) was preincubated in an aggregometer 
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Fig.3. Effects of PGI, on cyclic AMP levels and arachidonic Fig.4. Effects of colchicine on cyclic AMP levels and 
acid-induced aggregation and TXB, synthesis. PRP (0.5 ml) arachidonic acid-induced aggregation and TXB, synthesis. 
was preincubated for 1 min in an aggregometer at 37°C PRP (0.5 ml) was preincubated for 1 min in an aggregometer 
with CaCl, (2.5 mM) and for 15 s with PGI, (O-1000 ng/ml). at 37°C with CaCl, (2.5 mM) and colchicine (O-2 mM). The 
The samples were then incubated for 5 min with: A (upper samples were then incubated for 5 mm with: A (upper panel) 
panel) 250 pg arachidonic acid/ml; B (lower panel) 1000 &g 2.50 pg arachidonic acidjm1; B (lower panel) 1000 ng 
arachidonic acid/ml. Platelet aggregation was continuously arachidonic acid/ml. Platelet aggregation was continuously 
recorded. After addition of indomethacin (10 PM), the recorded. After addition of indomethacin (10 MM), the 
samples were rapidly frozen for TXB, analysis. Identically samples were rapidly frozen for TXB, analyses. Identically 
incubated samples were stopped with 0.5 ml 10% (w/v) incubated samples were stopped with 0.5 ml 10% (w/v) 
trichloroacetic acid for measurements of cyclic AMP. trichloroacetic acid for measurements of cyclic AMP. 
for 1 min at 37’C with CaCl, (2.5 mM) and colchicine 
(O-2 mM) prior to incubation with arachidonic acid 
(250 Kg/ml or 1000 fig/ml) for 5 min. Platelet 
aggregation was continuously monitored. Thereafter 
indomethacin (10 PM) was added and the samples 
were rapidly frozen for analyses of TXB,. Parallel 
samples were identically incubated and stopped with 
0.5 ml 10% (w/v) trichloroacetic acid for measurements 
of cyclic AMP. As shown in fig.4, colchicine inhibited 
platelet aggregation without elevating the cyclic AMP 
levels. Colchicine also decreased the formation of 
TXB, at the lower (250 pgfml) but not at the 
higher (1000 pg/ml) concentration of arachidonic 
acid. 
4. Discussion 
PGI, (prostacyclin) was used to study the effects 
of elevated cyclic AMP levels [ 17,l S] on platelet 
thromboxane formation. At low concentrations of 
PCIZ, the collagen-induced release of arachidonic acid 
was inhibited, as determined by direct measurements 
of arachidonic acid in PRP (Gg.1). This is in agreement 
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with reports howing that cyclic AMP inhibits 
arachidonic acid release from platelet phosphol~pids 
[l&-12]. 
PGIz prevents arachidonic acid-induced platelet 
aggregation [19]. With PGIz present, decreased con- 
version of exogenously added arachidonic acid to 
TXBz was observed at low but not at high concen- 
trations of the fatty acid (fig.2,3). Figure 3A shows 
that PGIz caused parallel dose-dependent i hibition 
of platelet a~regation and TX& synthesis when a 
low concent~tion of arachidonic acid was used. At 
a higher concentration of arachidonic acid, PG12 
inhibited platelet aggregation without affecting the 
synthesis of TXBz (f&.3@. This suggests hat cyclic 
AMP inhibits platelet aggregation atmultiple steps, 
one of which is beyond the synthesis of prostaglandin 
endoperoxides and thromboxanes fI0,13,20]. The 
latter effect is probabiy exerted by interference with 
contractile processes in platelets fI2]. 
The inhibition of arachidonic acid-induced TX& 
synthesis at low but not at higher substrate concen- 
trations indicates aEC, change of the prosta~la~d~ 
endoperoxide synthase. This could be a direct effect 
of cyclic AMP on the enzyme. Alternatively, the K, 
might decrease during platelet aggregation a d cyclic 
AMP counteract this effect by i~ib~t~ng a gregation, 
To distinguish between these two possibilities, 
colchicine was used as an agent which prevents 
aggregation without raising the levels of cyclic AMP 
(fig.4). The effects of colchicine on arachidonic acid- 
induced a~re~tion and TXB2 synthesis were 
identical to those of PG12 (fig.4). This supports the 
second alternative described above, namely that the 
effect of cycIic AMP on this enzyme is secondary to 
ir~h~b~tion of the a~regation. Further experiments 
regarding the influence of aggregation o  the platelet 
endoperoxide synthase are in progress. 
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